Google
VINC Stock Price & Analysis — Vincerx Pharma, Inc. Common Stock (Healthcare >> Biotechnology)
VINC FAQ
What is VINC's ROE?
Vincerx Pharma, Inc. Common Stock reports a Return on Equity (ROE) of -1,096.08%.
What is VINC's dividend yield?
Vincerx Pharma, Inc. Common Stock offers a dividend yield of 0.00%.
What is VINC's Quality Score?
Our AI rates VINC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VINC?
Our AI Timing Score for VINC is 2 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VINC belong to?
Vincerx Pharma, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
VINC AI Analysis Summary
Our AI summary for VINC: Vincerx Pharma, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -1,096.08%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 2/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.01
Price
0.00
(0.00%)
Day Change
|
|
|---|
VINC, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.01 |
| PBV / Sector |
0.03 / 5.21
GREAT
|
| Earning Per Share | -4.23 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
120.421590000000
|
| Average 1W Daily Value |
246.669560000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-07 08:12:30 |
| Symbol | VINC |
| Name | VINCERX PHARMA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.23 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 0.07 / 9,672.56 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1825 S. Grant Street, San Mateo, CA, United States, 94402
Phone: 650 800 6676
Website: https://vincerx.com
Sector: Healthcare >> Biotechnology
Description: Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies. It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor. The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021. Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap